Parkinson's Disease cost studies in Brazil: an evident scientific gap
DOI:
https://doi.org/10.33448/rsd-v10i15.22457Keywords:
Parkinson's disease; Cost of illness; Health economic; Health systems.Abstract
The financial impact of Parkinson's Disease on society has been widely discussed in recent decades and is expected to increase in the future, along with an aging population. However, the scarcity of studies on the cost of the disease in Brazil makes it difficult to carry out forecasts and calculations of future estimates, impairing the assessment of the economic impact on the individual's life and on health systems, both public and private. The objective of this research is to verify whether the scarcity of studies of this nature in Brazil is a reality, through a research of cost studies with the treatment of Parkinson's Disease carried out in recent years. A systematic literature review, based on a search for keywords on the topic, identified 27 articles that met the inclusion criteria and refinement filters applied to the initial portfolio. Of these, only two studies were carried out in Brazil (an original article and a systematic review), which proves the lack of studies on the subject in the country.
References
Bovolenta, T. M., Silva, S. M. C. A., Saba, R. A., Borges, V., Ferraz, H. B. & Felicio, A. C. (2017 a). Average annual cost of Parkinson’s disease in São Paulo, Brazil, with a focus on disease-related motor symptoms. Clinical Interventions in Aging 12: p.2095-2108
Bovolenta, T. M., Silva, S. M. C. A., Saba, R. A., Borges, V., Ferraz, H. B. & Felicio, A. C. (2017 b). Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease. Hindawi Parkinson's Disease, p.1-11
Brasil. (2008). Ministério da Saúde. 2008. Avaliação econômica em saúde: desafios para gestão no Sistema Único de Saúde. Brasília: Ministério da Saúde
Cubo, E., Alvarez, E., Morant, C., Cuesta, J. P., Martín, P. M., Génova, R. & Freire, J. M. (2005). Burden of Disease Related to Parkinson’s Disease in Spain in the Year 2000. Movement Disorders 20(11): p.1481-1487
Daneault, J. F., Carignan, B., Sadikot, A. F., Panisset, M. & Duval, C. (2013). Drug-induced dyskinesia in Parkinson’s disease: Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Medicine 11(73): p.1-18
Findley, L. J. (2007). The economic impact of Parkinson's disease. Parkinsonism and Related Disorders 13: p.8-12
García-Ramos, R., Valdés, E.L., Ballesteros, L., Jesús, S. & Mir, P. (2016). The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the brain. Neurología 31(6): p.401-413
Gaskin, J., Gomes, J., Darshan, S. & Krewski, D. (2017). Burden of neurological conditions in Canada. NeuroToxicology 61: p.2-10
Gil-Prieto, R., Pascual-Garcia, R., San-Roman-Montero, J., Martínez-Martin, P., Castrodeza-Sanz, J. & Gil-de-Miguel, A. (2016). Measuring the Burden of Hospitalization in Patients with Parkinson´s Disease in Spain. PLOS one 11(3): p.1-11
Jaglal, S. B., Guilcher, S. J. T., Bereket, T., Kwan, M., Munce, S., Conklin, J., Versnel, J., Packer, T., Verrier, M., Marras, C., Pitzul, K. B., & Riopelle, R. (2014). Development of a Chronic Care Model for Neurological Conditions (CCM-NC). BMC Health Services Research 14: p.1-12
Johnson, S. J., Diener, M. D., Kaltenboeck, A., Birnbaum, H. G., Grubb, E. & Siderowf, A. D. 2013. An economic model of Parkinson's disease: implications for slowing progression in the United States. Movement Disorders 28(3): p.319-326 (b)
Johnson, S. J., Kaltenboeck, A., Diener, M. D., Birnbaum, H., Grubb, E., Castelli-Haley, J. & Siderowf, A. D. (2013). Costs of Parkinson's disease in a privately insured population. PharmacoEconomics 31: p.799-806 (a)
Koay, L., Rose, J. & Abdelhafiz, A. H. (2018). Factors that lead to hospitalisation in patients with Parkinson disease—A systematic review. International Journal of Clinical Practice 72: p.1-5
Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V. & Jain, A. (2013). The current and projected economic burden of Parkinson's disease in the United States. Movement Disorders 28(3): p.311-318
Kruse, C. S., Kretschmer, A., Lipinski, M., Verheyen, D., Mengel, M., Balzer-Geldsetzer, S. & Lorenzl, et al. (2021). “Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study”. PharmacoEconomics 39(5): p.601–15.
Lindgren, P., von Campenhausen, S., Spottke, E., Siebert, U. & Dodel, R. (2005). Cost of Parkinson’s Disease in Europe. European Journal of Neurology 12(Suppl.1): p.68-73
Liu N., Babazono A., Kim S. A. & Li Y. (2021). Effect of Care Rehabilitation on Medical Expenses, Care Costs, and Total Costs of Elderly Individuals with Parkinson's Disease. Popul Health Manag. 2021 Mar 9. doi: 10.1089/pop.2020.0316.
Marques, N. G. S., Oliveira, M. I. S., Alves, M. N., Leão, S. S., Souza, S. D. B. & Lopes, G. S. (2020). Doença de Parkinson: os principais danos causados no indivíduo. Research, Society and Development, 9(10): p.1-13
Martínez-Martin, P., Rodriguez-Blazquez, C., Paz, S., Forjaz, M. J., Frades-Payo, B., Cubo, E., Pedro-Cuesta, J. & Lizán, L. (2015). Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis. PLOS one 10(12): p.1-16
Moraz, G., Garcez, A. S., Assis, E. M., Santos, J. P., Barcellos, N. T. & Kroeff, L. R. (2015). Estudos de custo-efetividade em saúde no Brasil: uma revisão sistemática. Ciência & Saúde Coletiva, 20(10): p.3211-3229
Mudiyanselage, S. B., Watts, J. J., Ochom, J. A., Lane, L., Murphy, A. T., Morris, M. E. & Iansek, R. (2017). Cost of Living with Parkinson’s Disease over 12 Months in Australia: A Prospective Cohort Study. Hindawi Parkinson's Disease, p.1-14
Oliveira, M. L., Santos, L. M. P. & Silva, E. N. (2014). Bases metodológicas para estudos de custos da doença no Brasil. Rev Nutr 27(5): p.585-595
Pinto, M. & Ugá, M. A. D. (2010). O custo de doenças tabaco-relacionadas para o Sistema Único de Saúde. Cad Saúde Pública 26(6): p.1234-1245
Prado, Mario Jr. & Jamora, R. D. (2020). Cost of Parkinson’s disease among Filipino patients seen at a public tertiary hospital in Metro Manila. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia 74: p.41–46.
Richy, F. F., Pietri, G., Moran, K. A., Senior, E. & Makaroff, L. E. (2013). Compliance with Pharmacotherapy and Direct Healthcare Costs in Patients with Parkinson’s Disease: A Retrospective Claims Database Analysis. Appl Health Econ Health Policy 11: p.395-406
Rodríguez-Blázquez, C., Forjaz, M. J., Lizán, L., Paz, S. & Martínez-Martín, P. (2015). Estimating the direct and indirect costs associated with Parkinson's disease. Expert Review of Pharmacoeconomics and outcomes research, p.1-23
Schlatter, R. P. (2016). Estudo de custos em doenças crônicas não transmissíveis: manejo da cardiopatia isquêmica e diagnostico precoce de câncer hereditário. Doctoral Thesis. Federal University of Rio Grande do Sul, Brasil
Secoli, S. R., Nita, M. E., Ono-Nita, S. K. & Nobre M. (2010). Avaliação de tecnologia em saúde: A análise de custo-efetividade. Arq Gastroenterol 47(4):p.329-333
Segel J. E. (2006). Cost-of-Illness studies: a primer. [s.l.]: RTI International. RTI-UNC Center of Excellence in Health Promotion Economics
Silva, E. N., Silva, M. T. & Pereira, M. G. (2016). Identificação, mensuração e valoração de custos em saúde. Epidemiol Serv Saúde 25(2): p.437-439
Tamás, G., Gulácsi, L., Bereczki, D., Baji, P., Takáts, A., Brodzky, V. & Péntek, M. (2014). Quality of life and costs in Parkinson's disease: a cross sectional study in Hungary. PLOS one 9(9): p.1-7
Vanni, T., Luz, P.M., Ribeiro, R. A., Novaes, H. M. D. & Polanczyk, C. A. (2009). Avaliação econômica em saúde: aplicações em doenças infecciosas. Cad. Saúde Pública 25(12): p.2543-2552
Viana, A., Pereira, J. S. & Vital, R. (2021). Estudo da neuropatia em pacientes com Doença de Parkinson: revisão de literatura. Research, Society and Development 10(7):p.1-15
Von Campenhausen, S., Winter, Y., Silva, A.R., Sampaio, C., Ruzicka, E., Barone, P., Poewe, W., Guekht, A., Mateus, C., Pfeiffer, K. P.,Berger, K., Skoupa, J., Botzel, K., Geiger-Gritsch, S., Siebert, U., Balzer-Geldsetzer, M., Oertel, W.H., Dodel, R. & Reese, J.P. (2011). Costs of illness and care in Parkinson's disease: an evaluation in six countries. European Neuropsychopharmacology 21: p.180-191
Watts, J. J., McGinley, J. L., Huxham, F., Menz, H. B., Iansek, R., Murphy, A. T., Waller, E. R. & Morris, M. E. (2008). Cost effectiveness of preventing falls and improving mobility in people with Parkinson Disesase: protocol for an economic evaluation alongside a clinical trial. BMC Geriatrics 8(23): p.1-8
Weir, S., Samnaliev, M., Kuo, T. C., Tierney, T. S., Autiero, S. W., Taylor, R. S. & Schrag, A. (2018). Short- and Long-Term Cost and Utilization of Health Care Resources in Parkinson's disease in the UK. Movement Disorders 33(6):p. 974- 981
Winter, Y., von Campenhausen, S. & Brozova, H. (2010). Costs of Parkinson’s disease in eastern Europe: a Czech cohort study. Parkinsonism and Related Disorders 16(1): p.51–56
Yang, J. X. & Chen, L. (2017). Economic burden analysis of Parkinson's disease patients in China. Hindawi Parkinson's Disease, p.1-7
Yoritaka, A., Fukae, J., Hatano, T., Oda, E. & Hattori, N. (2016). The direct cost of Parkinson disease at Juntendo medical university hospital, Japan. Internal Medicine 55 (2): p.113–119
Yu, W., Ravelo, A., Wagner, T. H. & Barnett, P. G. (2004). The relationships among age, chronic conditions, and healthcare costs. American Journal of Managed Care 10(12): p.909-916
Zhao, Y. J., Tan, L. C. S., Li, S. C., Au, W. L., Seah, S. H., Lau, P. N., Luo, N. & Wee, H. L. (2011). Economic burden of Parkinson's disease in Singapore. European Journal of Neurology 18: p.519-526
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Sávio Luís Oliveira da Silva; Osvaldo Luiz Gonçalves Quelhas; Júlio Vieira Neto; Marco Antônio Araújo Leite
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
